A survey of synthetic cannabinoid consumption by current cannabis users

Substance Abuse

Volumn 35, Issue 2, 2014, Pages 184-189

  Gunderson, Erik W ^a,b,c   Haughey, Heather M ^a   Ait Daoud, Nassima ^a   Joshi, Amruta S ^a   Hart, Carl L ^b,d  

^a UNIVERSITY OF VIRGINIA   (United States)

^b Och Spine at New York Presbyterian Hospitals   (United States)

^c Center for Wellness and Change   (United States)

^d NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

Author keywords

Cannabinoid K2; cannabinoid receptor agonists; cannabinoids; designer drugs,JWH 018; Spice; synthetic cannabinoid; tetrahydrocannabinol

Indexed keywords

CANNABINOID; STREET DRUG;

ADOLESCENT; ADULT; ADVERSE EFFECTS; ATTITUDE TO HEALTH; CANNABIS SMOKING; CLINICAL TRIAL (TOPIC); DRUG USE; FEMALE; HEALTH SURVEY; HUMAN; MALE; MARIJUANA ABUSE; MIDDLE AGED; PREVALENCE; PSYCHOLOGY; SMOKING; STATISTICS AND NUMERICAL DATA; UNITED STATES; YOUNG ADULT;

ADOLESCENT; ADULT; CANNABINOIDS; CLINICAL TRIALS AS TOPIC; DRUG USERS; FEMALE; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HEALTH SURVEYS; HUMANS; MALE; MARIJUANA ABUSE; MARIJUANA SMOKING; MIDDLE AGED; PREVALENCE; SMOKING; STREET DRUGS; VIRGINIA; YOUNG ADULT;

EID: 84901192582     PISSN: 08897077     EISSN: 15470164     Source Type: Journal    
DOI: 10.1080/08897077.2013.846288     Document Type: Article

References (30)

1. European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). EMCDDA 2009 Thematic Paper-Understanding the 'Spice' Phenomenon. Luxembourg: Office for Official Publications of the European Communities; 2009. Available at: http://www.emcdda.europa. eu/attachements.cfm/att 80086 EN EMCDDA Understanding%20-the%20'Spice'%20phenomenon 4Update%2020090813.pdf. Accessed July 28, 2013.
2. American Association of Poison Control Centers (AAPCC). Facts about "synthetic marijuana." Available at: https://aapcc.s3.ama zonaws.com/pdfs/topics/Synthetic Marijuana 6.2012.pdf. Accessed July 28, 2013.
3. US Drug Enforcement Agency. Chemicals Used in "Spice" and "K2" Type Products Now Under Federal Control and Regulation. News Release Number: 202-307-7977, March 1, 2011. Available at: http://www.justice. gov/dea/pubs/pressrel/pr030111.html. Accessed July 28, 2013
4. Johnston LD, O'Malley PM, Bachman JG, Schulenberg JE. Monitoring the Future National Results on Drug Use: 2012 Overview, Key Findings on Adolescent Drug Use. Ann Arbor: Institute for Social Research, The University of Michigan; 2013. Available at: www.monitoringthefuture.org/pubs/monographs/mtfoverview2012. pdf. Accessed August 23, 2013
5. US Department of Justice, Drug Enforcement Administration. Schedules of Controlled Substances: Temporary Placement of Three Synthetic Cannabinoids Into Schedule I. May 16, 2013. 21 CFR Part 1308 [Docket No. DEA-373]. Available at: http://www.deadiversion.usdoj.gov/fed regs/rules/2013/fr0516.htm. Accessed July 28, 2013.
6. United Nations Office on Drugs and Crime (UNODC). World Drug Report 2013. New York: United Nations; 2013. United Nations Publication, Sales No. E.13.XI.6. Available at: http://www.unodc. org/unodc/secured/wdr/wdr2013/World Drug Report 2013.pdf. Accessed July 28, 2013.
7. Auwarter V. Spice' and other herbal blends: harmless incense or cannabinoid designer drugs? J Mass Spectrom. 2009;44:832-837.
8. Psychonaut Web Mapping Research Group. Spice Report. London: Institute of Psychiatry, King's College London; 2009. Available at: www.psychonautproject. eu/documents/reports/Spice.pdf. Accessed July 28, 2013.
9. Vandrey R, Dunn KE, Fry JA, Girling ER. A survey study to characterize use of Spice products (synthetic cannabinoids). Drug Alcohol Depend. 2012;120:238-241.
10. Gunderson EW, Haughey HM, Ait-Daoud N, Joshi AS, Hart CL. "Spice" and "K2" herbal highs: a case series and systematic review of the clinical effects and biopsychosocial implications of synthetic cannabinoid use in humans. Am J Addict. 2012;21:320-326.
11. Pertwee RG. The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids:-9-tetrahydrocannabinol, cannabidiol and-9-tetrahydrocannabivarin. Br J Pharmacol. 2007;153:199-155.
12. Uchiyama N, Kikura-Hanajiri R, Ogata J, et al. Chemical analysis of synthetic cannabinoids as designer drugs in herbal products. Forensic Sci Int. 2010;198:31-38.
13. Substance Abuse and Mental Health Services Administration, Center for Behavioral Health Statistics and Quality. The DAWN Report: Drug-Related Emergency Department Visits Involving Synthetic Cannabinoids. Rockville, MD; December 4, 2012. Available at: http://www.samhsa.gov/data/2k12/DAWN105/SR105- synthetic-marijuana.htm. Accessed July 28, 2013.
14. Centers for Disease Control and Prevention. Acute kidney injury associated with synthetic cannabinoid use-multiple states, 2012. MMWR Morb Mort Wkly Rep. 2013;62:94-98.
15. Tofighi B, Lee JD. Internet highs-seizures after consumption of synthetic cannabinoids purchased online. J Addict Med. 2012;6: 240-241.
16. Hermanns-ClausenM,Kneisel S, SzaboB,Auẅarter V. Acute toxicity due to the confirmed consumption of synthetic cannabinoids: clinical and laboratory findings. Addiction. 2013;108:534-544.
17. Haney M. The marijuana withdrawal syndrome: diagnosis and treatment. Curr Psychiatry Rep. 2005;7:360-366.
18. Budney AJ, Vandrey RG, Hughes JR, Thostenson JD, Bursac Z. Comparison of cannabis and tobacco withdrawal: severity and contribution to relapse. J Subst Abuse Treat. 2008;35:362-368.
19. US Department of Justice, National Drug Intelligence Center. Drug Alert Watch: Use of Synthetic Cannabinoid Products by Teens and Young Adults Increasing. EWS Report 000006. May 18, 2010. Available at: http://www.justice. gov/archive/ndic/pubs41/41193/sw0006p.pdf. Accessed July 28, 2011.
20. Scalzo A. Epi-X The Epidemic Information Exchange. K2 Synthetic Marijuana Use Among Teenagers-Missouri, 2010. Available at: http://www.iowa.gov/odcp/ docs/Spice/K2Marijuana.pdf. Accessed August 23, 2013.
21. Vearrier D, Osterhoudt KC. A teenager with agitation: higher than she should have climbed. Pediatr Emerg Care. 2010;26:462-465.
22. American Psychiatric Association (APA). Diagnostic and Statistical Manual of Mental Disorders, 4th ed. (text revision) (DSM-IV-TR). Washington, DC: APA; July 2000.
23. Martin G, Copeland J, Gates P, Gilmour S. The Severity of Dependence Scale (SDS) in an adolescent population of cannabis users: reliability, validity and diagnostic cut off. Drug Alcohol Depend. 2006;83:90-93.
24. Smith PC, Schmidt SM, Allensworth-Davies D, Saitz R. Primary care validation of a single-question alcohol screening test. J Gen Intern Med. 2009;24:783-788.
25. National Institute on Alcohol Abuse and Alcoholism (NIAAA). The Physician's Guide to Helping Patients With Alcohol Problems. Bethesda, MD: National Institute of Health; 2005.
26. Terry-McElrath YM, O'Malley PM, Johnston LD. Middle and high school drug testing and student illicit drug use: a national study 1998-2011. J Adolesc Health. 2013;52:707-715.
27. Zimmermann US, Winkelmann PR, Pilhatsch M, et al. Withdrawal Phenomena and dependence syndrome after the consumption of "Spice Gold." Dtsch Arztebl Int. 2009;106:464-467.
28. M̈uller H, SperlingW, K̈ohrmann M, Huttner HB, Kornbuber J, Maler JM. The synthetic cannabinoid Spice as a trigger for an acute exacerbation of cannabis induced recurrent psychotic episodes. Schizophr Res. 2010;108:309-310.
29. Every-Palmer S. Synthetic cannabinoid JWH-018 and psychosis: an explorative study. Drug Alcohol Depend. 2011;117: 152-157.
30. Degenhardt L, Hall W. Extent of illicit drug use and dependence, and their contribution to the global burden of disease. Lancet. 2012;379:55-70.